Insider Selling: TherapeuticsMD Inc (TXMD) CEO Sells 184,000 Shares of Stock

TherapeuticsMD Inc (NASDAQ:TXMD) CEO Robert G. Finizio sold 184,000 shares of TherapeuticsMD stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $6.63, for a total transaction of $1,219,920.00. Following the transaction, the chief executive officer now directly owns 18,485,559 shares in the company, valued at approximately $122,559,256.17. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of NASDAQ:TXMD traded up $0.08 during mid-day trading on Monday, reaching $6.70. The company had a trading volume of 2,161,300 shares, compared to its average volume of 2,496,695. The company has a current ratio of 7.88, a quick ratio of 7.79 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $1.53 billion, a PE ratio of -17.97 and a beta of 1.54. TherapeuticsMD Inc has a one year low of $4.34 and a one year high of $7.66.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Monday, July 30th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The company had revenue of $3.80 million during the quarter, compared to the consensus estimate of $4.23 million. TherapeuticsMD had a negative return on equity of 80.75% and a negative net margin of 582.86%. The company’s revenue for the quarter was down 11.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.10) EPS. research analysts predict that TherapeuticsMD Inc will post -0.63 earnings per share for the current year.

Several large investors have recently bought and sold shares of TXMD. Public Employees Retirement Association of Colorado raised its holdings in shares of TherapeuticsMD by 2,545.7% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 1,071,500 shares of the company’s stock worth $6,686,000 after purchasing an additional 1,031,000 shares during the period. BlackRock Inc. grew its stake in TherapeuticsMD by 4.4% in the 2nd quarter. BlackRock Inc. now owns 14,533,524 shares of the company’s stock valued at $90,690,000 after buying an additional 608,470 shares in the last quarter. OppenheimerFunds Inc. grew its stake in TherapeuticsMD by 17.4% in the 2nd quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock valued at $12,058,000 after buying an additional 286,123 shares in the last quarter. Voya Investment Management LLC grew its stake in TherapeuticsMD by 7.7% in the 2nd quarter. Voya Investment Management LLC now owns 3,419,174 shares of the company’s stock valued at $21,336,000 after buying an additional 242,995 shares in the last quarter. Finally, Raymond James & Associates grew its stake in TherapeuticsMD by 26.6% in the 2nd quarter. Raymond James & Associates now owns 719,568 shares of the company’s stock valued at $4,490,000 after buying an additional 151,335 shares in the last quarter. 66.14% of the stock is currently owned by institutional investors.

Several equities analysts have commented on TXMD shares. Oppenheimer set a $12.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, May 30th. ValuEngine cut shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a report on Friday, June 1st. BidaskClub raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Friday, June 8th. JPMorgan Chase & Co. began coverage on shares of TherapeuticsMD in a report on Friday, June 15th. They issued an “overweight” rating and a $11.00 price target on the stock. Finally, Cantor Fitzgerald set a $26.00 price target on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Monday, July 30th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $15.33.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Recommended Story: How to Invest in an Index Fund

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply